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1. Introduction 
It is now evident that despite an enormous progress in our understanding of molecular 
mechanisms and processes which operate in tumor cells, this knowledge does not directly 
translate into more efficient treatment and cure of cancer patients. At the origin of the 
inefficiency of cancer treatment is inherent or therapy-induced resistance of tumor cells to 
therapeutic agents. Many different mechanisms of drug resistance have been described and 
characterized, including elevated expression of membrane drug transporters, changed drug 
activation and/or detoxification, more efficient repair of drug-induced lesions and non-
functional cell death pathways. Another reason for an inefficiency of currently available 
cancer treatment modalities can be related to cellular heterogeneity of tumors and targeting 
by anticancer drugs only some tumor cells in the population, which are more sensitive to 
applied therapeutic agents. In this situation, anticancer treatment can lead to the selection of 
drug resistant tumor cells and cytostatic rather than cytotoxic effect. The origin of these 
more resistant cells in tumor cell population was classically perceived as a result of 
spontaneous or therapy-induced gene mutations, making surviving tumor cells less 
sensitive to anticancer agents. According to the alternative hypothesis, heterogeneity of 
tumor cell population, also in its response to drug treatment, can result from a clonal 
expansion of rare malignant stem cells which may differentiate and produce tumors.  
Cancer was proposed to originate from stem cells more than 150 years ago (see Wicha et al., 
2006 and references therein) and this idea re-appeared in the early sixties of the last century, 
first for leukemias (Bruce & van der Gaag, 1963) and later for epithelial tumors (Hamburger 
& Salmon, 1977). About the same time, Pierce and Wallace provided experimental evidence 
for the existence of cellular hierarchy in tumors, where malignant undifferentiated cells give 
rise to benign well-differentiated cells (Pierce & Wallace, 1971). A few years later, Potter 
proposed a new model of oncogenic transformation according to which tumor cells resulted 
from blocked differentiation of their progenitors (Potter, 1978). Collectively, a new paradigm 
of cancer origin was established in which malignant stem cells with de-regulated self-
renewal and differentiation mechanisms are responsible for tumor initiation and growth. 
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Recent explosion of reports providing experimental data that confirm this hypothesis is 
undoubtedly associated with a growing knowledge about normal stem cells and their 
potential practical applications in regenerative medicine.  
It is known for years that embryonic cells may spontaneously form teratocarcinomas when 
transplanted into mice. Secondly, when adult differentiated cells are induced by oncogenes 
and transcription factors to trans-differentiate into pluripotent cells (iPSCs) with stem-like 
features, they form tumors in experimental animal models with a relatively high frequency 
(for recent review see Yamanaka & Blau, 2010). Accumulating evidence show that there are 
remarkable similarities between the reprogramming processes and oncogenic 
transformation of adult somatic cells and similar factors regulate both pluripotency and 
tumorigenicity. For example, it was shown that cell reprogramming is regulated by p53, p16 
(INK4a) and p21 (Banito et al., 2009) similarly to tumors. Both reprogramming and 
oncogenic transformation require specific combinations of collaborating genes, that can 
produce a less differentiated cell able to proliferate and self-renew indefinitely. All four 
factors, which were initially shown to reprogram somatic cells to iPS cells, are 
overexpressed in at least some types of tumor, and two of them — c-myc and Klf4 — are 
established oncogenes. Similarly, reprogramming is less efficient in cells which are close to 
senescence suggesting that, similarly as in tumorigenicity, cellular senescence protects cells 
from induced pluripotency (Banito et al., 2009). Together, one can conclude that studies on 
reprogramming of adult somatic cells into iPS cells provide probably the best experimental 
evidence that the idea of abnormal stem cells as the origin of tumors may actually be true. It 
seems that today it is more and more important to delineate similarities and differences 
between tumor cells and iPS/stem cells as it may provide insights into cancer origin and 
potentially give new clues for anticancer drug screening and therapy (for recent review see 
Tilkorn et al., 2010).  
There are many controversies related to the cancer stem cell paradigm and its importance 
for anticancer therapy, some of them will be presented in the following sections of this 
chapter. To begin with, there is a problem with terminology since the term ‘cancer stem 
cells’ (CSC), that is used quite commonly, is somewhat confusing as it relates cancer cells to 
true stem cells, and this is still hypothetical. Introduction of the name ‘stemloids’ by 
Blagosklonny is less ambiguous since it implies some similarity to stem cells, however, 
pointing to important differences (Blagosklonny, 2005). Another term that is in use, ‘tumor-
initiating cells’, is also confusing since it suggests that these are the cells that have initiated 
the tumor in vivo. The most relevant is probably the term ‘tumor-propagating cells’, 
introduced by Kelly et al (Kelly et al., 2007) and Hong et al (Hong et al., 2008), that points to 
the ability of tumor cells to propagate both in vitro and in vivo. In this review, we will use the 
term cancer stem cells (CSCs) as it still is the most popular in the current literature. 
It is still not clear as to whether the cancer stem cell paradigm can be applied to all human 
tumors or it is restricted to leukemias and several types of solid tumors. Moreover, cancer 
stem cells have been shown to be resistant to anticancer agents but molecular mechanisms, 
which are responsible for drug resistance phenotype of these cells, are far from being fully 
characterized. Finally, it is not at all clear how to include the knowledge about cancer stem 
cells, that we accumulated so far, into new methodologies and assays used in drug 
screening, both in cytotoxicity measurements in vitro and antitumor assays in animal 
models. Without these practical tools, it will be impossible to screen for new drugs and drug 
combinations that will allow us to eradicate CSCs and in consequence tumors. 
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2. Identification and quantitation of cancer stem cells in human tumors 
The existence of rare stem-like cells is being experimentally confirmed in a growing number 
of different tumor types (for review see Reya et al., 2001; Pardal et al., 2003), including 
myeloid leukemia, breast carcinomas, glioblastoma, melanoma, lung and colon carcinomas 
(Quintana et al., 2008; Li et al., 2008; Meng et al., 2009; Yeung et al., 2010). One of the most 
astonishing discoveries concerning CSCs was identification of cancer cells with stem-like 
properties in cell populations from established tumor cell lines maintained in vitro (Yeung et 
al., 2010). This discovery has important implications as it opens a possibility to use tumor 
cells cultivated in vitro in drug screening and find new compounds which are able to kill 
CSCs (see section 5 of this chapter). 
One of the controversial issues in the field is whether all known tumor types are 
heterogeneous and consist of a small fraction of CSCs that is able to produce tumors in vivo 
and differentiate to non-CSC cells. It has been shown that human colon carcinoma HCT-116 
cells do not contain a hierarchy of tumor cells as concerns production of tumors in nude 
mice (Kai et al., 2009, Diettfeld et al., 2010). Another example is glioblastoma C6 cells where 
the majority of cell population formed tumors in vivo although these cells have only 0.4% 
side population (SP) cells (Zheng et al., 2007). Does it mean that in these tumor cell 
populations all cells have features of CSC? Is it a typical situation or rare examples between 
tumors of epithelial origin? Similarly, the fraction of CSCs in different human tumors is very 
divergent. This is at least partially related to the fact that estimations of the number of CSCs 
are based on several different methodologies (discussed below). Moreover, all of them 
assume that the CSC fraction is homogenous and can be clearly distinguished from non-CSC 
cells, and this has never been firmly established. In contrast, there are reasons to believe that 
CSC cells, with the capacity for long-term self-renewal, constitute an identifiable 
subpopulation of tumor cells but there is a hierarchy of stem-like cancer cells, as has been 
recently shown for glioblastomas (Chen et al., 2010). 
The most popular strategy to identify CSCs uses specific cell surface markers, such as CD34, 
CD44, CD117, CD133, integrin a2b1, ESA (epithelial specific antigen) and others or their 
combinations. A different approach is to mark side population (SP) cells based on the 
exclusion of Hoechst 33342 dye, as the SP fraction is postulated to be enriched in CSCs 
(Hirschmann-Jax et al., 2004; Patrawala et al., 2005). However, there are reports showing 
that expression of membrane markers can not reliably distinguish between CSCs and non-
CSCs and cells expressing specific stem cell markers can be as tumorigenic in nude mice as 
tumor cells which are devoid of specific stem cell markers. This has been particularly well 
documented for a commonly used stem cell marker CD133 in glioblastomas (Beier et al., 
2007; Prestengarden et al., 2010; Chen et al., 2010) but also in colon carcinoma HCT-116 cells 
(Dittfeld et al., 2010). 
CSCs are also frequently quantitated based on the number of cells which are tumorigenic, 
when transplanted into immunocompromized mice. Although most researchers of the 
cancer stem cell community consider the latter method as the most reliable, there are also 
reports suggesting that one has to be very cautious when interpreting results of these tests. 
It seems, for example, that one may greatly underestimate the frequency of tumorigenic cells 
in tumor cell population as it depends on the animal model used. Recent studies showed 
that the detection of tumorigenic melanoma cells injected into mice can be increased by 
several orders of magnitude if more highly immunocompromised NOD/SCID interleukin-2 
receptor gamma chain null (Il2rg(-/-)) mice are used in the modified xenotransplanation 
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assay and tumor cells are injected in Matrigel (Quintana et al., 2008). In these conditions, 
the estimated fraction of melanoma CSCs from cancer patients increased to about 25%, 
suggesting that these cells are much more common, at least in some human tumors. 
Therefore, it is possible that estimations of CSC number by tumorigenicity assay may be 
biased by the way this assay is performed i.e. animal model used (nude mice vs. SCID 
mice, or SCID mice with no residual immunity), the number of tumor cells injected into 
animals, etc. 
Some authors postulate that human tumor cells may also differ in their ability to produce 
tumors in mice and this factor may also greatly influence estimations of CSCs fraction 
(Baker, 2008). If this is true, one may argue whether the xenotransplanation assay really 
detects a rare subset of cells that can propagate tumors (i.e. which are tumorigenic) or a rare 
subset of human tumor cells that can establish themselves in mice. It should also be noted 
that staining by Hoechst 33342 may be toxic for CSCs as shown for C6 glioblastoma cells 
and cell sorting by flow cytometry, that is based on Hoechst 33342 stainability, may 
considerably lower tumorigenicity and, in effect, hamper accurate estimation of CSC 
fractions (Shen et al., 2008). 
The origin of CSCs both in in vivo tumor models and in tumor cell lines maintained in in 
vitro culture is another controversial issue. According to the standard CSC hypothesis, the 
initial CSC originates from normal stem cells or by re-programming more differentiated 
progenitor cells by oncogenic insults or both. Propagation of these initial CSCs is based on 
asymmetrical cell division and production of other CSCs and non-CSCs. However, it should 
be noted that other mechanisms have been proposed by which CSCs may be formed. These 
include epithelial to mesenchymal transition induced in non-CSC cells from mammary 
carcinoma that has recently been shown to be involved in CSC formation (Mani et al., 2008; 
Morel et al., 2008; Santisteban et al., 2009). Some other phenomena related to anticancer 
therapy may also be implicated in CSC formation. De-differentiation of non-CSC cells into 
CSCs may be favored by stress-induced factors released after drug treatment. Moreover, 
many anticancer drugs induce growth arrest in G2 and M phases that frequently leads to 
polyploidization. Drug-induced polyploidy usually leads to cells death by mitotic 
catastrophe (for review see Vakifahmetoglu et al., 2008) but in some situations the process of 
de-polyploidization may occur and result in CSC production (Erenpreisa & Craigg, 2010; 
Salmina et al., 2010). Polyploidy and consequently cancer stem cells may be also produced 
by cell-cell fusion (Rizyj et al., 2006; Dittmar et al., 2009). These effects can also explain the 
effect of the so-called ‘oncogenic resistance’, the phenomenon frequently observed in the 
clinical situation, where after treatment with therapeutic agents tumor cells are both more 
malignant and resistant to anticancer therapy, compared to untreated tumor cells. It seems 
that ‘oncogenic resistance’ can not be attributed to resistance phenotype of CSCs (discussed 
in Dittmar et al., 2009). One possibility is that DNA damage induced by anticancer treatment 
may lead to gross genomic re-arrangements (both genetic and epigenetic) that result not 
only in acquiring by tumor cells the stem-like phenotype but also in drug resistance. 
Changes in tumor cell genome may occur during de-polyploidization of polyploid cells, 
followed by abnormal mitotic divisions that lead to reduction of cellular DNA content. CSCs 
can also be generated by cell-cell fusion that is also stimulated by anticancer treatment 
(Dittmar et al., 2009). According to this scenario, fusion between e. g. CSC and non-CSC cells 
may result in tumor cells with stem properties. This approach has been used to produce 
pluripotent cells from adult somatic cells (discussed in Pralong et al., 2006). 
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3. Properties of stem cells and CSCs: similarities and differences 
One of the issues concerning CSCs that needs clarification is which properties are shared 
between normal stem cells and cancer stem cells. This is particularly important for potential 
therapies directed toward CSCs that should spare normal stem cells. CSCs are defined to 
have three features: i) represent a minor population of a tumor (typically 0.1-2% of all cells 
but may be as high as 25% - see previous section); ii) have the property of self-renewal; iii) 
are the only cells within the tumor which are capable of immortal growth and production of 
the tumor in vivo. It follows that tumor cell population is composed of relatively rare CSCs 
and ‘committed’ or ‘differentiated’ non-CSC tumor cells with possibly limited life span. 
Important properties of normal stem cells include self-renewal, as well as pluripotency i. e. 
the ability of stem cells to differentiate to many functionally distinct cell types. In addition to 
that, stem cells are characterized by their very limited proliferation potential, as stem cells 
cells divide only occasionally and in response to very specific intra- and extracellular 
signals.  
Some of these stem cell features cannot directly be applied to CSCs. Most of the available 
literature data show that CSCs proliferate quite rapidly, although doubling times are 
frequently much slower compared to the non-stem tumor population (Ropolo et al., 2009; 
Ishimoto et al., 2010). An extreme case can be leukemia stem cells which are commonly 
dormant but can be induced to proliferate by specific cytokines or anticancer agents such as 
arsenic oxide (Essers & Trumpp, 2010; Thomas & Cannas 2010). Secondly, one of the 
features of stem cells is their ability to produce more differentiated cell progeny. 
Accordingly, cells of many tumor types are able to differentiate reversibly or irreversibly 
into different cell types. For example, irreversible differentiation of myeloid leukemia HL-60 
cells into monocytes or granulocytes is induced by sodium butyrate, forskolin and 
hexamethylene bisacetamide (Breitman et al., 1990) or re-activation of wild-type p53 (Soddu 
et al., 1994). Similarly, colon carcinoma HT-29 cells may be reversibly differentiated into 
enterocytes or mucin-producing lineages (Chakrabarty et al., 1992; Choi et al., 2000; Demers 
et al., 2009), and another colon carcinoma SW1222 cells differentiate into enterocytes, 
enteroendocrine and goblet cells (Yeung et al., 2010). Yet another classical example is breast 
carcinomas such as MCF-7 cells which may also be induced to differentiate by sodium 
butyrate and forskolin (Wasserman et al., 1987; Guilbaud et al., 1990). Conversely, nuclear 
transfer studies showed that the phenotype of at least some cancer cells (as shown for 
melanomas) can be reversed to a pluripotent state that allows apparently normal 
differentiation (Hochedlinger et al., 2004). Unfortunately, it is not known whether tumor cell 
nuclei used for nuclear transfer were from CSCs or non-CSC cells. Another example of 
tumor cell plasticity related to cell differentiation is the work of Kulesa et al where 
metastatic phenotype of melanoma cells was shown to be reversed by embryonic milieu 
(Kulesa et al., 2006). These data point to the important role of tumor microenvironment for 
the maintenance of tumor cell phenotype. 
As mentioned above, there are also tumor cells e. g. HCT-116 where there is apparently no 
hierarchy of cells differing in tumorigenicity (Kai et al., 2009) and which have little or no 
capacity to differentiate, therefore, in these tumors majority (if not all) cells can be 
considered as CSC. This suggests the existence at least two types of tumors: these with CSC 
sub-population which are able to differentiate and those, which contain only cells with CSC 
features and no or limited differentiation capacity. An intriguing question remains whether 
in cells like HCT-116, differentiation of CSC cells is irreversibly blocked or it may still be 
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activated in stress conditions imposed for example by a drug treatment. This is important 
given that in tumor cell populations, where no hierarchy is observed, drug response and 
sensitivity should be more homogenous so in vitro testing for cytotoxic activity gives more 
reliable results as for drug concentrations required to eradicate all tumor cells. In contrast, if 
tumors contain populations of cells, with various in their differentiation status, cytotoxic 
action of antitumor drugs may also be heterogeneous. In that case, drug screening with 
mixed tumor cell populations can provide information about overall sensitivity of tumor 
cells only if the cytotoxic effect is determined in such a way that distinguishes killing or not 
of both CSCs and more differentiated non-CSC cells.  
Finally, according to a classical stem cell hypothesis differentiated non-CSC cells have a 
limited life span. However, very little is known about molecular mechanisms which can 
explain the potential limited proliferation capacity of non-stem tumor cells and the ultimate 
fate of non-stem tumor cells. This may be related to the fact that relatively little research 
activity has been devoted to non-CSC tumor cells.  
It is well known that in cell culture there is always a small fraction of apoptotic cells but 
where the fraction of dead cells comes from, whatever low it is, is not clear. Is this slow but 
progressive shedding of differentiated tumor cells? It is possible that these dying ‘mature’ 
tumor cells reached the survival limit due to the number of cells divisions. Another 
interesting point is whether there is a ‘Hayflick-like limit’ for differentiated tumor cells, if it 
at all exists? If positive, what is the mechanism of survival limit of tumor cells if it most 
probably does not depend on telomere-length maintenance? Are CSCs immortal cells? 
It should be remembered that molecular mechanism(s) of cell senescence-like process is still 
active in tumor cells as it can be induced by several different stimuli such as expression of 
oncogenes, stress conditions or DNA damage (Roninson, 2003). This process resembles 
replicative senescence but is usually not associated with telomere shortening. Surprisingly, 
relatively recent studies have shown that human hepatocarcinomas and immortal breast 
carcinoma cells both in vitro and in animal in vivo models produce spontaneously senescent 
progeny (Ozturk et al., 2006). It is not clear which type of cells (i.e. CSCs or non-CSCs) had 
limited proliferation potential and were able to undergo cellular senescence. Analysis of cell 
clones generated from single cells of breast carcinoma tumor cell lines in vitro showed that 
within 12 different cells lines tested there were two groups. One group (5 cell lines) 
produced senescent cells (positive for SA-β-Gal/negative for BrdU incorporation) with high 
frequency (5-40%) whereas the other group produced less that 5% of senescent cells 
(Mumcuoglu et al., 2010). Based on these features, the authors classified all breast cell lines 
studied as senescent cell progenitor (SCP) and immortal cell progenitor (ICP) cell subtypes. 
Interestingly, ICP cells were much more tumorigenic in immunodeficient mice compared to 
SCP cell lines. Even more importantly, more tumorigenic ICP cells were deficient in their 
ability to generate more differentiated progeny, pointing to the fundamental difference 
between these cell subtypes. It would be extremely interesting to find out whether these two 
types of cells, with different abilities to produce differentiated progeny and ability to 
undergo senescence-associated growth arrest, are also present in other tumor types. Equally 
important would be to establish whether these two types of cell clones correspond to CSC 
and non-CSC cells.  
The presence of senescent cells in tumor cell population have been confirmed by others for 
prostate, head and neck squamous cell and breast carcinomas (Locke et al., 2005; Li et al., 
2008). Molecular mechanism of spontaneous senescence induced in tumor cells was 
associated with repression of hTERT expression, that led to telomere shortening (Ozturk et 
www.intechopen.com
Cancer Stem Cells in Drug Resistance and Drug Screening: 
Can We Exploit the Cancer Stem Cell Paradigm in Search for New Antitumor Agents?   
 
429 
al., 2006), therefore, it followed a classical replicative senescence program. These results 
provide an experimental evidence for the reversibility of cancer cell immortality by 
repression of telomerase expression. This is probably not surprising considering the fact that 
expression of telomerase is switched on in most tumor cells and is regulated by a number of 
different genes, including SIP1, hSIR2, c-myc, Mad1, Menin, Rak, and Brit1 as well as TGF-β 
and SMAD pathway (Wang et al., 1998; Verschueren et al., 1999; Lin & Elledge, 2003). 
Therefore, the epigenetic mechanism responsible for upregulation of hTERT expression and 
telomerase activity in a majority of tumor cells is potentially reversible and can be turned off 
again.  
4. Resistance of CSCs to anticancer treatment: possible molecular 
mechanisms 
It is well established that a fraction of cells in a tumor frequently survives anticancer 
treatment when exposed to radiation and cytotoxic drugs. This drug resistant subpopulation 
of tumor cells may constitute of CSCs, and in this way, these cells may be responsible for the 
failure of most, if not all, anticancer therapies, as these cells are postulated to be inherently 
resistant to anticancer agents. Based on that, a new therapeutic strategy has been proposed 
in which drugs should specifically target CSCs, and this will allow us to eradicate tumors. 
However, finding of these CSC-specific agents is only possible if we characterize possible 
mechanisms responsible for resistance of CSCs to anticancer therapy (summarized in Figure 
1). Another important question is whether CSCs are resistant to all therapeutic agents or 
there are drug-specific resistance phenotypes, associated with changes in the functioning of 
defined intracellular pathways in these cells. Moreover, drug resistance of CSCs may 
involve several mechanisms and results from changes in different intracellular pathways. It 
is also not clear if molecular mechanisms responsible for CSC therapeutic resistance are 
shared across different tumor types. 
The most straightforward mechanism that can be responsible for lower activity of anticancer 
drugs toward CSCs is overexpression of ABC transporters. One of the methods for CSC 
determination is based on lower stainability of CSC-containing fraction, the so-called SP 
cells, to fluorescent dye Hoechst 33342 (discussed in section 2 of this chapter). Low 
fluorescence of SP cells after Hoechst 33342 staining is attributed to overexpression of ABC 
pumps by CSCs, frequently ABCG2. Since many antitumor drugs are substrates for ABC 
membrane transporters, this can lead to typical multidrug resistance phenotype of CSCs. It 
should be noted, however, that Hoechst-based assay for SP fraction may give misleading 
results. It has been shown that ABCC1-overexpressing cells HL-60/Adr (Marsch et al., 1986) 
contain more than 90% of SP cells (Patrawala et al., 2005) that is not necessarily associated 
with increased CSC content.  
Up-regulation of ABC transporters is a typical feature of both normal stem cells and CSCs 
(Patrawala et al., 2005; Nakai et al., 2009; Yamamoto et al., 2009; Angelastro & Lamé, 2010; 
Jin et al., 2010). However, this can not be a general phenomenon as our results obtained for 
non-small cell lung carcinoma A549 cells showed that CSCs cells isolated after treatment 
with anticancer drugs (dexrazoxane, amsacrine) did not overexpress ABC transporters and 
had unchanged drug sensitivity (Sabisz & Skladanowski, 2009).  
It is interesting that overexpression of ABC transporters in stem cells and CSCs correlates 
with the level of several stem cell markers such as CD133, nestin, CD117 (c-kit) (Yamamoto 
et al., 2009; Adhikari et al., 2010) or Notch-1 and Nanog (Patrawala et al., 2005; Bourguignon 
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Fig. 1. The proposed mechanisms responsible for drug resistance phenotype of cancer stem 
cells. 
et al., 2008). Inherent overexpression of ABC pumps in these cells is dependent on stem 
factors such as Oct4, that is present both in embryonic stem cells and CSCs (Wang et al., 
2010) and may be induced by anticancer treatment (Nakai et al., 2009). Similarly, interaction 
between stem cell related transcription regulators STAT1/3 and Nanog leads to activation of 
STAT1/3 and increased expression of several genes, including ABCB1 transporter 
(Bourguignon et al., 2008). Given the fact that CSCs frequently overexpress ABC 
transporters, it is interesting to note that salinomycin, that has been shown to selectively kill 
mammary carcinoma CSCs (Mani et al., 2008) is the inhibitor of ABCB1 pump (Ricconi et al., 
2010).  
Alternative drug resistance mechanism of CSCs may be associated with lower proliferation 
potential of these cells compared to ‘committed’ non-CSC cells. In this situation, anticancer 
treatment that targets actively proliferating cells, such as DNA damaging agents, mitotic 
spindle poisons or antimetabolites, are less effective in killing CSCs than mature 
‘differentiated’ cancer cells. Although this issue has not been systematically studied, several 
groups reported that CSCs isolated from gastric carcinomas and glioblastomas have either 
increased (Beier et al., 2008) or elongated (Ropolo M et al., 2009; Ishimoto et al., 2010; 
Thomas & Cannas, 2010) doubling time compared to a bulk tumor cell population or non-
CSC cells. Surprisingly, changes in doubling time are not always associated with differences 
in the distribution between cell cycle phases (Ropolo M et al., 2009). As discussed above, in 
hematological malignancies, leukemia stem cells usually do not proliferate. 
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It is not clear whether longer doubling times are characteristic for CSCs in all types of 
tumors and if they result from fundamental differences in cell cycle regulation between 
CSCs and differentiated tumor cells. It should be noted that determination of a doubling 
time for CSCs and non-CSCs was performed in the artificial situation where these two cell 
populations grow separately, and this may influence their growth rate. The existence of a 
possible interaction between CSCs and non-CSC cells and other cells from tumor 
microenvironment can be concluded based on results obtained in colon carcinoma, glioma 
and leukemia models (Evers et al., 2010; Raaijmakers et al., 2010; Saito et al., 2010; 
Vermeulen et al., 2010). Perturbations of mechanism(s) of cross-regulation of cell growth, 
which potentially exist between CSCs and non-CSCs, may also influence drug sensitivity 
(see next paragraph).  
Another mechanism that can be proposed to explain drug resistance phenotype of CSCs is 
related to differences between CSCs and non-CSCs in the functionality of cell cycle 
checkpoints and enhanced repair of drug-induced damage. However, this is controversial as 
there are contradictory data in the available literature concerning this issue. Defective intra-
S checkpoint but intact G2 checkpoints were documented in glioblastoma CD133-positive 
stem-like cells isolated from patient tumor samples. These cells showed increased sensitivity 
to irradiation with respect to the standard glioblastoma model, established glioma cell lines 
(McCord et al., 2009a). Interestingly, when radiosensitivities of CD133-positive and negative 
cells from glioma cell lines were compared, CD133+ stem-like cells showed radioresistance 
(McCord et al., 2009a). Other studies have shown that glioma CSCs as well as epithelial cells 
with stem-like properties, preferentially activate DNA damage response and cell cycle 
checkpoints after treatment with ionizing irradiation both in vivo and in vitro and this can be 
related to their radioresistance (Bao et al., 2006; Facchino et al., 2010; Harper et al., 2010). 
Molecular mechanism that was responsible for lower sensitivity to irradiation of glioma 
CSCs involved increased activity of two intra-S and G2 checkpoint kinases, Chk1 and Chk2. 
Inhibition of these kinases by a selective chemical inhibitor debromohymenialdisine 
sensitized CSC cells to irradiation (Bao et al., 2006; Harper et al., 2010). Interestingly, 
increased Chk1 and Chk2 activity was also shown in untreated glioma CSCs (Ropolo et al., 
2009), suggesting that enhanced basal activation of checkpoint kinases in CD133+ cells may 
determine their cell cycle delay and contribute to their radioresistance by allowing more 
time for DNA repair of damages.  
The role of DNA repair in radio- and chemoresistance of CSCs is less clear. In one report, no 
differences in DNA base excision or single-strand break repair nor in resolution of γ-H2AX 
nuclear foci were found in radioresistant CD133+ CSCs compared with CD133− glioma cells 
(Ropolo et al., 2009). However, earlier study with glioma tumor cells treated with 
temozolomide showed increased rather than decreased sensitivity of CD133-positive CSCs 
(Beier et al., 2008). The drug produced essentially no cell death but a prominent growth 
inhibitory effect was observed specifically for glioma stem cells. In contrast, temozolomide 
did not inhibit the growth of progenitor and differentiated cells derived from CSC but 
showed a selective growth inhibitory effect toward glioma CSCs. Temozolomide is the most 
commonly used chemotherapeutic agent in the treatment of glioblastomas and induces 
DNA adducts which are repaired by the DNA repair protein O6-methylguanine-DNA-
methyltransferase (MGMT). MGMT is expressed only in a subgroup of glioblastomas since 
its promoter is frequently methylated in this type of tumor cells (Hegi et al., 2005). 
Accordingly, temozolomide concentrations required to deplete glioma CD133+ CSCs was 
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substantially higher (about 10-fold) in tumor cells expressing MGMT. However, 
combination of the drug with the MGMT inhibitor 6-buthylguanine sensitized stem cell-like 
glioma cells with high MGMT expression to the deleterious effects of temozolomide.  
Finally, radio- and chemoresistance of CSCs may be associated with the interplay between 
DNA damage response induced by anticancer treatment and  regulated by the ATM/ATR 
pathway as well as survival signaling mediated by PI3K/Akt pathway (for recent review 
see Skladanowski et al., 2009). It was postulated that regulation of DNA damage response 
induced by irradiation in CSCs follows the classical ATM-dependent mechanism (Facchino 
et al., 2010; Golding et al., 2009). Furthermore, a specific ATM inhibitor KU-60019 reduced 
basal activation of Akt by downregulation of its Ser-473 phosphorylation and this led to 
reduced glioma cell migration and invasion (Golding et al., 2009). In this way, inhibition of 
DNA damage response by KU-60019 is associated with downregulation of pro-survival 
signaling mediated by Akt and sensitizes glioma cells to irradiation. The important role of 
Akt pathway in stemness and invasion but also in response to cancer treatment has been 
confirmed by others in gliomas (Molina et al., 2010; Wang et al., 2010), but also in lung, 
colon and mammary carcinomas (Sabisz & Skladanowski, 2009; Wang et al., 2010; Zhang et 
al., 2010). Interestingly, there may be a cross-talk between at least some stem cell markers, 
such as CD44, and PI3 kinase/Akt-related survival pathways, can also lead to 
chemotherapeutic drug resistance, as shown in breast tumor cells (Miletti-González et al., 
2005). Collectively, these results raise important therapeutic implications for a concurrent 
combination of DNA damaging drugs and inhibitors of Akt pathway to target CSCs 
(Mueller et al., 2009; Sabisz & Skladanowski, 2009; Zhang et al., 2010). 
5. Perspectives: can we exploit the CSC paradigm in drug screening? 
There is accumulating experimental evidence that CSCs are resistant to standard anticancer 
therapies. This suggests that screening procedures, in which cytotoxic and antitumor effect 
induced by antitumor agents is evaluated, should be modified in such a way to select drugs 
or drug combinations which are able to target CSCs. Current in vitro drug screening 
systems, with the most widely known the NCI 60 cell line model, are based on a relatively 
short-term drug treatment and continuous drug exposure of tumor cells. The cytotoxic effect 
is evaluated using different tests which are sensitive to drug-induced changes of tumor cell 
number and/or viability, using typically the MTT assay (reduction of the MTT stain to 
formazan), chemiluminescence-based measurements of intracellular ATP content.  
Several different experimental approaches were proposed for screening of CSC-specific 
antitumor agents (see Figure 2). In one of them the standard cytotoxicity assays are performed 
using CSC populations which are sorted based on the expression of membrane stem markers 
by e.g. flow cytometry or immunomagnetic cell sorting. The cytotoxic effect toward CSCs is 
then compared with that induced in non-CSCs. A simpler variant of this methodology is to 
sort the SP cells as a fraction of cells with high content of CSCs. This method can also be 
applied to evaluate antitumor effect of drugs in vivo using animal models.  
Another way of enrichment of tumor cell populations with CSCs is the generation of cell 
spheres at conditions when the attachment of tumor cells to the substratum is prevented. 
This could be realized in several different ways, the most typical involves low attachment 
substrata where cell dishes are covered both by natural (e. g. agar) or synthetic polymers. In 
a more technically sophisticated approach, magnetic levitation is used where tumor cells are 
cultivated in hydrogels on magnetic iron oxide nanoparticles, with magnetic-controlled 
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Fig. 2. Currently available strategies which can be used to screen for drugs or drug 
combinations with selective activity toward cancer stem cells. 
levitation system (Souza et al 2010). Interestingly, magnetically levitated human 
glioblastoma cells showed similar protein expression profiles to those observed in human 
tumor xenografts (Souza et al 2010). The sphere formation models were used to determine 
the cytotoxic activity of antitumor drugs of different tumor types, including mammary 
carcinomas (mammospheres), gliomas (neurospheres) and lung carcinomas (Setoguchi et al., 
2004; Patrawala et al., 2005; Levina et al., 2008; Bertolini et al., 2009). It is worth mentioning 
that the seminal work of Robert Kerbel and his co-workers on drug resistance of tumor cells, 
associated with what was at this time called the ‘social effect’ (Kobayashi et al 1993), can be 
related today to the CSC phenomenon.   
Yet another possibility is to treat bulk tumor populations with different antitumor agents 
and the fraction of tumor cells, which are able to proliferate after drug treatment, is 
subsequently estimated based on the colony formation ability or production of spheres on 
low adherent plates by drug-treated tumor cells. The latter approach was successfully 
applied for lung, breast and ovarian carcinoma cells (Levina et al., 2008, Sabisz & 
Skladanowski, 2009). In addition, to confirm that cells surviving after drug treatment are 
truly CSCs, cells may be also analysed for the expression of stem markers. 
The features of CSCs that were presented in this chapter suggest that there are two groups 
of potential problems related to the described above screening assays and possibly other 
screening methods aimed at the selection of anti-CSC drugs. These problems may 
potentially makes it very difficult to apply the CSC paradigm in search for new therapeutic 
strategies to kill CSCs. First group is associated with problems which we call ‘technical’ such 
as cell systems used and estimation of the cytotoxic effect of potential drugs toward CSCs. 
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Classical cytotoxicity assays such as MTT or ATP-based chemoluminescence tests can not be 
applied in sphere formation systems. In multicellular spheroids, there is a problem with the 
penetration of biochemical stains used in these assays and mitochondrial activity of cells 
present inside spheroids is greatly reduced, that underestimates the number of viable cells 
in spheroids. On the other hand, colony formation assays are difficult to be performed in 
high throughput systems where drug screening is highly automated and a very small 
number of cells is used. In this situation, results may be irreproducible and experimental 
errors may be exceedingly high. As for cell systems used to screen for anti-CSC drugs, it 
should be borne in mind that cell spheres are not always enriched in CSCs (Gasparini et al., 
2010). In addition, there are no generally accepted stem markers of CSC that makes it very 
difficult to reliably separate these cells from non-CSCs very difficult (discussed in section 2 
of this chapter). In addition, expression of some stem markers may be functionally inter-
related and downregulation of marker 1 expression may lead to increased/decreased 
expression of marker 2. This kind inter-relationship in membrane marker expression has 
been shown in breast carcinoma cells for β1 integrin and EGFR (Wang et al 1998). 
Cell growth conditions used to cultivate CSCs to be used in drug screening may also be 
problematic. Typical growth media containing serum may change cancer stem cell 
phenotype and their characteristic gene expression profile. It has been shown that 
maintenance of glioblastoma CSCs in media with defined growth factors such as β−FGF and 
EGF (stem conditions) preserve more closely stem-like phenotype of these cells but serum 
(differentiation conditions) induces irreversible cell differentiation (Lee et al 2006). Similarly, 
oxygen concentration in cell culture may be critical for the preservation of the CSC 
phenotype. It has been shown that the SP fraction in tumor cell population in vivo is 
increased in hypoxic regions (Das et al 2008). This effect was reproduced with the same cell 
system by exposure of cultured cells in vitro to hypoxia. The authors propose that a highly 
tumorigenic SP cells migrate to the area of hypoxia that may serve as a niche for the highly 
tumorigenic fraction of SP cells and can be induced in vitro. Moreover, increasing evidence 
suggest that hypoxia has the potential to inhibit tumor cell differentiation that leads to 
increased fraction of CSCs in hypoxic regions that results result in accelerated the initiation 
and growth of tumors (Calabrese et al 2008). An elegant study has shown that growing 
CD133(+) cells sorted from three GB neurosphere cultures at 7% oxygen reduced their 
doubling time and increased the self-renewal potential as reflected by clonogenicity 
(McCord et al., 2009b). Furthermore, at 7% oxygen, the cultures exhibited an enhanced 
capacity to differentiate along both the glial and neuronal pathways. As compared with 
20%, growth at 7% oxygen resulted in an increase in the expression levels of the neural stem 
cell markers CD133 and nestin as well as the stem cell markers Oct4 and Sox2 (McCord et 
al., 2009b). Collectively, these reports point to still greatly underestimated role of hypoxia in 
the maintenance of the CSC properties. 
Another group of problems is related to our current understanding of the CSC paradigm. It 
seems that the most fundamental question is whether a tumor develops from a homogenous 
but scarce population of CSCs, as the classical hypothesis of cancer stem cells proposes. In 
this case, it makes very much sense to search for the Achille's heel of such a population and 
use it as a drug target for selective killing of CSCs. However, an emerging picture is that 
CSCs do not constitute a homogenous population of cells, with defined molecular markers 
and cell features, as it is still widely believed. There is also accumulating evidence that the 
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phenotype of CSCs is not stable and, at least in some situations, is reversible. In addition, 
differences between CSCs and ‘mature’ tumor non-CSC cells are frequently only 
quantitative not qualitative, and result from stochastic rather than deterministic processes. 
Drug selectivity can be a difficult problem to resolve in anti-CSCs therapies. All the already 
characterized drug resistance mechanisms, which are active in CSCs and responsible for 
their drug resistance phenotype, operate in tumor cells in general, others are characteristic 
for normal stem cells. For all these reasons, selection of new therapeutic approaches that 
specifically target CSCs is a particularly challenging task. To achieve this goal, it is 
important to define optimal therapeutic targets in CSC sub-populations as well as to 
implement the improved drug screening systems. 
In our opinion a modern and more effective antitumor therapy should include both CSC 
and non-CSC drugs, ideally targeting both cell populations with high efficacy. Therapeutic 
eradication of CSCs by their selective targeting with antitumor drugs may be a very 
dangerous therapeutic approach for several reasons. First, paradoxically many available 
literature data suggest that very selective antitumor drugs frequently are not efficacious in 
the clinical practice. Second, we still do not know how many cell generations are required 
for a tumor to degenerate, as a result of CSC depletion. It is possible that by targeting only 
CSCs the remaining non-CSCs may well kill the patient before a tumor disappears. In 
addition to that, although formally non-CSC tumor cells are more sensitive to anticancer 
agents, so they should not survive drug treatment, there is still a possibility that drugs can 
initiate cellular processes leading to trans-differentiation of non-CSC to CSC phenotype (de-
polyploidization, EMT etc.).  
Together, more detailed fundamental knowledge is still required about molecular 
mechanisms responsible for CSC formation, both inherent and therapy-induced, and CSC 
phenotype in general. Only after understanding these mechanisms will it be possible to find 
new anticancer treatment modalities which will be able to kill or arrest CSC growth by 
inhibiting critical intracellular pathways associated with stemness or CSC differentiation or 
both.  
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